PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: A systematic review and meta-analysis

Giampaolo Tortora, Emilio Bria, Ettore D'Argento, Emanuele Vita, Roberto Iacovelli, Antonio Rossi, Giulia Sartori, Sara Monteverdi, Fiorella Lombardo, Isabella Sperduti, Michele Milella, Sara Pilotto

Risultato della ricerca: Contributo in rivistaArticolo in rivista

6 Citazioni (Scopus)

Abstract

Aim: With the final aim to explore the first-line treatment options for non-small-cell lung cancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according to type of treatment-add-on strategy: immunotherapy in combination versus standard chemotherapy-based regimens. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were extracted and cumulated. Results: Seven trials (4278 patients) were included. The addition of immunotherapy to standard chemotherapy-based regimens significantly increased OS (HR 0.74; p = 0.001) and PFS (HR 0.61; p < 0.0001) compared with standard-of-care in NSCLC patients in first-line setting. Conclusion: Immunotherapy-based regimens constantly improved OS and PFS compared with chemotherapy in first-line treatment of nononcogene-addicted NSCLC.
Lingua originaleEnglish
pagine (da-a)921-930
Numero di pagine10
RivistaImmunotherapy
Volume11
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • NSCLC
  • PD-1
  • PD-L1
  • atezolizumab
  • first line
  • immunotherapy
  • meta-analysis
  • nivolumab
  • pembrolizumab

Fingerprint

Entra nei temi di ricerca di 'PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: A systematic review and meta-analysis'. Insieme formano una fingerprint unica.

Cita questo